Progenics Pharmaceuticals, Inc. Board Approves $15 Million Share Repurchase Program

April 25, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that its Board of Directors has approved a share repurchase program to acquire up to $15 million of its outstanding common shares.

Twitter
LinkedIn
Facebook
Email
Print